Cyclerion Therapeutics (NASDAQ:KRSA) Coverage Initiated by Analysts at Stifel Nicolaus

Research analysts at Stifel Nicolaus started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research report issued on Monday, Briefing.com reports. The firm set a “buy” rating and a $43.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 39.66% from the stock’s current price.

A number of other analysts also recently commented on KRSA. Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. UBS Group assumed coverage on Cyclerion Therapeutics in a research note on Friday. They set a “buy” rating and a $55.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $49.00.

Cyclerion Therapeutics Price Performance

KRSA traded down $1.12 during trading on Monday, reaching $30.79. The stock had a trading volume of 4,422 shares, compared to its average volume of 313,500. The company has a market capitalization of $20.63 million, a price-to-earnings ratio of -2.65 and a beta of 1.75. Cyclerion Therapeutics has a 1-year low of $7.19 and a 1-year high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.